COMPASS Pathways (CMPS) Q2 2024 earnings summary

Executive summary

• Advanced phase III COMP360 program in treatment-resistant depression, with top-line COMP005 data expected Q4 2024 and COMP006 data mid-2025; recruitment and retention rates are strong.

• Positive phase 2 results for COMP360 in PTSD showed sustained symptom improvement and no serious adverse events.

• Leadership strengthened with appointments of Lori Englebert as Chief Commercial Officer, Gino Santini as Chairman, and Michael Gold as Chief R&D Officer.

• No therapeutic candidates approved for sale; operations funded by equity, debt, and warrant exercises.

• No major surprises from recent regulatory Adcom; trial designs align with FDA expectations for rigor and safety.

Financial highlights

• Q2 2024 net loss was $38.1 million ($0.56/share), with a six-month net loss of $73.3 million ($1.11/share), up from $52.5 million in the prior year period.

• Research and development expenses rose to $54.0 million for the six months ended June 30, 2024.

• Cash and cash equivalents were $228.6 million as of June 30, 2024, expected to fund operations into 2026.

• Q2 2024 cash used in operations was $34.4 million, within guidance of $32–$38 million.

• Long-term debt was $29.4 million as of June 30, 2024.

Outlook and guidance

• Top-line data for COMP005 expected in Q4 2024, possibly slipping into January; COMP006 primary endpoint expected by mid-2025.

• Q3 2024 net cash used in operating activities expected between $32 million and $38 million; full-year guidance $110–$130 million, assuming receipt of 2023 R&D tax credit.

• Cash runway expected to fund operations into 2026, but future viability depends on ability to raise additional capital.

• Longer-term follow-up data (26 weeks) for COMP005 and COMP006 will be released 5–6 months after primary endpoint data.

• Research and development costs expected to increase as phase III and other clinical programs progress.